[Comment on the article: "Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in...

The FINDRISC test is a scale developed in Finland by Lindström and Tuomilehto to determine a patient's risk of developing type 2 diabetes. This scale has been accepted and valid in many countries, including Spain, Greece, Norway, and Germany. Having widely accepted instruments opens the possibility of conducting studies between different countries or cultures, which implies evaluating the various items of the instrument in the most accurate way possible. It is important to note that in Mexico, according to ENSANUT 2022, the prevalence of diagnosed diabetes was 12.6% and that of undiagnosed diabetes was 5.8%, resulting in a total prevalence of diabetes of 18.3%. In contrast, in Finland, for the year 2021, the prevalence was 7.7%, which denotes a large difference in the number of people living with diabetes in both countries.